Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro

Antiviral Research

Volumn 88, Issue 2, 2010, Pages 143-151

  Lai, Bonnie E ^a   Geonnotti, Anthony R ^a   DeSoto, Michael G ^a   Montefiori, David C ^b   Katz, David F ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusion; Drug delivery; Gels; HIV prevention; Microbicides; Placebos

Indexed keywords

HYDROXYETHYLCELLULOSE; METHYLCELLULOSE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG DELIVERY SYSTEM; FEMALE; FEMALE GENITAL SYSTEM; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL TRANSMISSION; SPERM; VAGINA DISCHARGE; VAGINA EPITHELIUM; VIRION; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CELLULOSE; DIFFUSION; DRUG DESIGN; FEMALE; GELS; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHYLCELLULOSE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77958150858     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.08.006     Document Type: Article

References (64)

1. Abdool Karim S., Coletti A., Richardson B., Ramjee G., Hoffman I., Chirenje M., Taha T., Kapina M., Maslankowski L., Soto-Torres L. Safety and effectiveness of vaginal microbicides BufferGel and 0. 5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 Trial. 16th Conference on Retroviruses and Opportunistics Infections 2009.
2. Balimane P.V., Chong S., Morrison R.A. Current methodologies used for evaluation of intestinal permeability and absorption. Journal of Pharmacological and Toxicological Methods 2000, 44:301-312.
3. Barnhart K.T., Pretorius E.S., Timbers K., Shera D., Shabbout M., Malamud D. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 2004, 70:498-505.
4. Behrens I., Stenberg P., Artursson P., Kissel T. Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX .... Pharmaceutical Research 2001.
5. Behrens I., Pena A.I.V., Alonso M.J., Kissel T. Nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption. Pharmaceutical Research 2002.
6. Boukari H., Brichacek B., Margolis L., Nossal R. HIV-virions appear to be trapped by human cervical mucus. Biophysical Journal 2009, 96:35a.
7. Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Research 2010, 85:142-158.
8. Cecchelli R., Dehouck B., Descamps L., Fenart L., BuE;e-Scherrer V., Duhem C., Lundquist S., Rentfel M., Torpier G., Dehouck M.P. In vitro model for evaluating drug transport across the blood-brain barrier. Advanced Drug Delivery Reviews 1999, 36:165-178.
9. Cone R. Barrier properties of mucus. Advanced Drug Delivery Reviews 2009, 61:75-85.
10. Cutler B., Justman J. Vaginal microbicides and the prevention of HIV transmission. The Lancet Infectious Diseases 2008, 8:685-697.
11. das Neves J., Bahia M.F. Gels as vaginal drug delivery systems. International Journal of Pharmaceutics 2006, 318:1-14.
12. Dezzutti C.S., James V.N., Ramos A., Sullivan S.T., Siddig A., Bush T.J., Grohskopf L.A., Paxton L., Subbarao S., Hart C.E. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrobial Agents and Chemotherapy 2004, 48:3834-3844.
13. Feldblum P.J., Adeiga A., Bakare R., Wevill S., Lendvay A., Obadaki F., Olayemi M.O., Wang L., Nanda K., Rountree W. SAVVY Vaginal Gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008, 3:e1474.
14. Forbes B., Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics 2005, 60:193-205.
15. Geonnotti A.R., Katz D.F. Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. Biophysical Journal 2006, 91:2121-2130.
16. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. The Lancet 2001, 357:1149-1153.
17. Guenthner P.C., Secor W.E., Dezzutti C.S. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infection and Immunity 2005, 73:4155-4160.
18. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nature Reviews Immunology 2005, 5:783-792.
19. Halpern V., Ogunsola F., Obunge O., Wang C., Onyejepu N., Oduyebo O., Taylor D., McNeil L., Mehta N., Umo-Otong J., Otusanya S., Crucitti T., Abdellati S. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE 2008, 3:e3784.
20. Hammonds J., Chen X., Fouts T., DeVico A., Montefiori D., Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus Type 1 primary isolates by Gag-Env pseudovirion immunization. Journal of Virology 2005, 79:14804-14814.
21. Henderson M.H., Peters J.J., Walmer D.K., Couchman G.M., Katz D.F. Optical instrument for measurement of vaginal coating thickness by drug delivery formulations. Review of Scientific Instruments 2005, 76.
22. Henderson C., Walmer P., Owen B., Lavine K. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 2007, 75:142-151.
23. Hu J., Gardner M.B., Miller C.J. Simian Immunodeficiency Virus Rapidly Penetrates the Cervicovaginal Mucosa after Intravaginal Inoculation and Infects Intraepithelial Dendritic Cells. Journal of Virology 2000, 74:6087-6095.
24. Jay J.I., Shukair S., Langheinrich K., Hanson M.C., Cianci G.C., Johnson T.J., Clark M.R., Hope T.J., Kiser P.F. Modulation of viscoelasticity and HIV transport as a function of pH in a reversibly crosslinked hydrogel. Advanced Functional Materials 2009, 19:2969-2977.
25. Johnston M.I., Fauci A.S. An HIV vaccine-evolving concepts. The New England Journal of Medicine 2007, 356:2073-2081.
26. Justin-Temu M., Damian F., Kinget R., Van Den Mooter G. Intravaginal gels as drug delivery systems. Journal of Womens Health (Larchmt) 2004, 13:834-844.
27. Kalichman S.C., Di Berto G., Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sexually Transmitted Diseases 2008, 35:55-60.
28. Karim Q.A., Karim S.S.A., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B.M., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010, on behalf of the CAPRISA 004 Trial Group. 10.1126/science.1193748.
29. Kilmarx P.H., Paxton L. Need for a true placebo for vaginal microbicide efficacy trials. The Lancet 2003, 361:785-786.
30. Lagakos S.W., Gable A. Methodological challenges in biomedical HIV prevention trials. 2008, Institute of Medicine. Committee on the Methodological Challenges in, H.I.V.P.T., National Academies Press, Washington, DC.
31. Lai B.E., Henderson M.H., Peters J.J., Walmer D.K., Katz D.F. Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophysical Journal 2009, 97:2379-2387.
32. Lai S.K., Hida K., Shukair S., Wang Y.-Y., Figueiredo A., Cone R., Hope T.J., Hanes J. Human immunodeficiency virus Type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. Journal of Virology 2009, 83:11196-11200.
33. Maguire R.A., Zacharopoulos V.R., Phillips D.M. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sexually Transmitted Diseases 1998, 25:494-500.
34. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus Type 1 vaccines. Journal of Virology 2005, 79:10103-10107.
35. Masse B., Boily M.-C., Dimitrov D., Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerging Themes in Epidemiology 2009, 6:5.
36. Mathias N.R., Yamashita F., Lee V.H.L. Respiratory epithelial cell culture models for evaluation of ion and drug transport. Advanced Drug Delivery Reviews 1996, 22:215-249.
37. Mauck C.K., Katz D.F., Sandefer E.P., Nasution M.D., Henderson M., Digenis G.A., Su I., Page R., Barnhart K. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception 2008, 77:195-204.
38. Microbicide Trials Network Fact Sheet: HPTN 035 at a glance 2009, Microbicide Trials Network, Pittsburgh, PA.
39. Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Wietgrefe S., La Franco-Scheuch L., Compton L., Duan L., Shore M.D., Zupancic M., Busch M., Carlis J., Wolinsky S., Wolinksy S., Haase A.T. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. Journal of Virology 2005, 79:9217-9227.
40. Montefiori, D.C., 2010. Standardized Assessments of Neutralizing Antibodies for HIV/AIDS Vaccine Development, Durham.
41. Morcock D.R., Thomas J.A., Gagliardi T.D., Gorelick R.J., Roser J.D., Chertova E.N., Bess J.W., Ott D.E., Sattentau Q.J., Frank I., Pope M., Lifson J.D., Henderson L.E., Crise B.J. Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins. Journal of Virology 2005, 79:1533-1542.
42. Ndesendo V.M., Pillay V., Choonara Y., Buchmann E., Bayever D., Meyer L.C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS Pharmscitech 2008, 9:505-520.
43. Owen D.H., Katz D.F. A vaginal fluid simulant. Contraception 1999, 59:91-95.
44. Owen D.H., Katz D.F. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. Journal of Andrology 2005, 26:459-469.
45. Peterson L., Nanda K., Opoku B., Ampofo W., Owusu-Amoako M., Boakye A., Rountree W., Troxler A., Dominik R., Roddy R., Dorflinger L. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007, 2:e1312.
46. Phillips D. Intravaginal formulations to prevent HIV infection. Perspectives in Drug Discovery and Design 1996, 5:213-224.
47. Pontier C., Pachot J., Botham R., Lenfant B., Arnaud P. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. Journal of Pharmaceutical Sciences 2001, 90:1608-1619.
48. Qian H., Sheetz M.P., Elson E.L. Single particle tracking. Analysis of diffusion and flow in two-dimensional systems. Biophysical Journal 1991, 60:910-921.
49. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., Meehan M.O., Lutalo T., Gray R.H. Viral load and heterosexual transmission of human immunodeficiency virus Type 1. The New England Journal of Medicine 2000, 342:921-929. The Rakai Project Study Group.
50. Rohan L.C., Sassi A.B. Vaginal drug delivery systems for HIV prevention. The AAPS Journal 2009, 11:78-87.
51. Saxton M.J. Single-particle tracking: the distribution of diffusion coefficients. Biophysical Journal 1997, 72:1744-1753.
52. Schwartz J.L., Ballagh S.A., Kwok C., Mauck C.K., Weiner D.H., Rencher W.F., Callahan M.M. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007, 75:136-141.
53. Skoler-Karpoff S., Ramjee G., Ahmed K., Altini L., Plagianos M.G., Friedland B., Govender S., De Kock A., Cassim N., Palanee T., Dozier G., Maguire R., Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 2008, 372:1977-1987.
54. Suh J., Dawson M., Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Advanced Drug Delivery Reviews 2005, 57:63-78.
55. Tao W., Richards C., Hamer D. Short communication: enhancement of HIV infection by cellulose sulfate. AIDS Research and Human Retroviruses 2008, 24:925-929.
56. Tien D., Schnaare R.L., Kang F.R., Cohl G., McCormick T.J., Moench T.R., Doncel G., Watson K., Buckheit R.W., Lewis M.G., Schwartz J., Douville K., Romano J.W. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. Aids Research and Human Retroviruses 2005, 21:845-853.
57. Trapp S., Turville S.G., Robbiani M. Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV. Journal of Leukocyte Biology 2006, 80:1076-1083.
58. Truskey G.A., Yuan F., Katz D.F. Transport Phenomena in Biological Systems 2009, Pearson Education, Inc., Upper Saddle River, NJ. 2nd ed.
59. Turville S., Aravantinou M., Miller T., Kenney J., Teitelbaum A., Hu L., Chudolij A., Zydowsky T., Piatak M., Bess J., Lifson J., Blanchard J., Gettie A., Robbiani M. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE 2008, 3:e3162.
60. Van Damme L., Govinden R., Mirembe F.M., Guédou F., Solomon S., Becker M.L., Pradeep B.S., Krishnan A.K., Alary M., Pande B., Ramjee G., Deese J., Crucitti T., Taylor D., Group C.S.S. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. The New England Journal of Medicine 2008, 359:463-472.
61. Van Herrewege Y., Michiels J., Waeytens A., De Boeck G., Salden E., Heyndrickx L., van den Mooter G., de Bethune M.-P., Andries K., Lewi P., Praet M., Vanham G. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Research 2007, 74:111-124.
62. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Medicine 2003, 9:343-346.
63. Wawer M.J., Gray R.H., Sewankambo N.K., Serwadda D., Li X., Laeyendecker O., Kiwanuka N., Kigozi G., Kiddugavu M., Lutalo T., Nalugoda F., Wabwire-Mangen F., Meehan M.P., Quinn T.C. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases 2005, 191:1403-1409.
64. Weiler A.M., Li Q., Duan L., Kaizu M., Weisgrau K.L., Friedrich T.C., Reynolds M.R., Haase A.T., Rakasz E.G. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. Journal of Virology 2008, 82:4154-4158.